WESTFORD, Mass., March 15, 2012 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced it plans to introduce a speed and power enhancement for two of its most popular multi-purpose systems. The Company expects to launch the Elite+ and Apogee+ Aesthetic Workstations at the 70th Annual Meeting of the American Academy of Dermatology March 16-20 in San Diego, California.
“With enhanced power, these new workstations can treat 44 percent more area per pulse than our current Elite and Apogee models,” said Michael Davin, Cynosure’s President and Chief Executive Officer. “The increased speed of treatment translates into higher patient throughput for practitioners and reduced treatment time for patients, while ensuring the safety, comfort and reliability that patients depend on. These next-generation systems demonstrate our focus on delivering innovative technology improvements that enable practitioners to provide the most comprehensive suite of products for applications that are in high demand.”
Elite+ is a multi-purpose, dual-wavelength system used to remove unwanted hair, treat facial and leg veins and rejuvenate the skin by removing age spots and sun-damage -- all in a single visit. The revolutionary technology of the Elite+ combines two optimal wavelengths in one system: the 755-nm Alexandrite and the 1064-nm Nd:YAG. Practitioners can switch between wavelengths during a single procedure, allowing them to select the most appropriate laser for any hair or skin type.
Apogee+ is equipped with a 755-nm Alexandrite laser that permanently removes hair on a wide variety of skin types. In addition, it treats benign epidermal pigmented lesions such as age spots, sunspots and freckles. Current U.S. customers will be able to upgrade their existing Elite and Apogee workstations to the plus versions.
In addition to these enhanced workstations at AAD, Cynosure (Booth # 3707) is featuring its new CellulazeWorkstation, the world’s only FDA-cleared, minimally invasive aesthetic device for cellulite reduction. Cellulaze reduces cellulite in just one treatment by restoring the normal structure of the skin and underlying connective tissue. It is designed to diminish the lumpy pockets of fat, release the areas of skin depression typifying cellulite and increase the elasticity and thickness of the skin.
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce the appearance of cellulite and treat Onychomycosis. Cynosure’s products include a broad range of laser- and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the Apogee+, Elite+ and Cellulaze, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economy and lending environment and their effects on the aesthetic laser industry, Cynosure’s history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure’s most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure’s views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure’s views as of any date subsequent to the date of this press release.
Contact:
Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com
SOURCE Cynosure, Inc.
